At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 161 enrolled
Drug / intervention
Sufentanil Tablet 30 mcg +1 moredrug
Likely dose
Sufentanil Tablet 30 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Post-Operative Pain in Patients After Abdominal Surgery
In Brief
A Phase 3 clinical trial evaluating Sufentanil Tablet 30 mcg and Placebo Tablet for Post-Operative Pain. Completed, enrolled 161 participants across 4 sites.
Detailed Summary
The purpose of this study is to compare the efficacy and safety of the sublingual Sufentanil Tablet (ST) 30 mcg to the sublingual Placebo Tablet (PT) for the short-term management of moderate-to-severe acute post-operative pain in patients after abdominal surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-Operative Pain
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartFeb 2015
First PostedFeb 2015
Primary CompletionJun 2015
Study CompletionAug 2015
TodayJul 2026
First PostedFeb 5, 2015
Enrollment StartFeb 1, 2015
Primary CompletionJun 1, 2015
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 11.4 years ago
Interventions
Sufentanil Tablet 30 mcgdrug
Placebo Tabletdrug